T cell receptor peptide therapy triggers autoregulation of experimental encephalomyelitis

Research output: Contribution to journalArticlepeer-review

200 Scopus citations


Encephalitogenic T cells specific for myelin basic protein share common Vβ8 peptide sequences in their T cell receptor (TCR) that can induce autoregulatory T cells and antibodies that prevent clinical signs of experimental autoimmune encephalomyelitis (EAE). It is not known, however, if TCR peptides can treat established disease. To test its therapeutic value, TCR-Vβ8-39-59 peptide was injected into rats with clinical signs of EAE. This treatment reduced disease severity and speeded recovery, apparently by boosting anti-Vβ8 T cells and antibodies raised naturally in response to encephalitogenic Vβ8+ T cells. These results demonstrate that synthetic TCR peptides can be used therapeutically, and implicate the TCR-Vβ8-39-59 sequence as a natural idiotope involved in EAE recovery. Similarly, human TCR peptides may be effective in enhancing natural regulation of autoreactive T cells that share common V genes.

Original languageEnglish (US)
Pages (from-to)430-432
Number of pages3
Issue number4992
StatePublished - 1991

ASJC Scopus subject areas

  • General


Dive into the research topics of 'T cell receptor peptide therapy triggers autoregulation of experimental encephalomyelitis'. Together they form a unique fingerprint.

Cite this